Abstract
In December 2019 COVID-19 appeared as a new pandemic that has claimed the lives of millions of people around the world. This article presents a regional analysis of COVID-19 in Mexico. Due to the comorbidities of Mexican society, the new pandemic implies a higher risk for the population. The study period runs from April 12 to October 5, 2020 (761 665 Patients). In this proposal we apply a unique methodology of random matrix theory in the moments of a probability measure that appears as the limit of the empirical spectral distribution by the Wigner semicircle law. The graphical presentation of the results is done with Machine Learning methods in the SuperHeat maps. With this is possible to analyze the behavior of patients who tested positive for COVID-19 and their comorbidities. We conclude that the most sensitive comorbidities in hospitalized patients are the following three: COPD, Other Diseases and Renal Diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
NO funding supported
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data used here are open data, and it can be found on the website of the federal government in Mexico in the section of the Secretariat of Epidemiology.Historical bases COVID-19. Available on: https://www.gob.mx/cms/uploads/attachment/file/604001/Datos_abiertos_hist_ricos_2020.pdf
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
https://www.gob.mx/cms/uploads/attachment/file/604001/Datos_abiertos_hist_ricos_2020.pdf
Abbreviations
- (D)
- Diabetes
- (CO)
- COPD
- (A)
- Asthma
- (IM)
- Immunosuppression
- (HY)
- Hypertension
- (CA)
- Cardiovascular
- (RE)
- chronic kidney disease
- (OB)
- obesity
- (OD)
- others diseases
- (R1)
- Region 1
- (R2)
- Region 2
- (R3)
- Region 3
- (R4)
- Region 4
- (R5)
- Region 5
- (N)
- Non-hospitalized patient
- (H)
- Hospitalized patients
